Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Illumina Signs Agreement to Acquire NextBio

Published: Tuesday, October 29, 2013
Last Updated: Tuesday, October 29, 2013
Bookmark and Share
Acquisition will strengthen Illumina's informatics portfolio, enable accelerated adoption of next-generation sequencing in current and new markets.

Illumina, Inc. has announced that it has signed a definitive agreement to acquire Santa Clara-based NextBio, a leader in clinical and genomic informatics.

NextBio's powerful big-data platforms aggregate and analyze large quantities of phenotypic and genomic data for research and clinical applications.

With the addition of NextBio's platform upon completion of the acquisition, Illumina will be able to offer customers enterprise level bioinformatics solutions that accelerate the discovery of new associations between the human genome and disease, and ultimately, enable the application of those discoveries within healthcare.

"This agreement with NextBio demonstrates Illumina's unwavering commitment to drive the adoption of sequencing in new markets and vastly improve the genomic information workflow," said Jay Flatley, President and CEO of Illumina.

Flatley continued, "NextBio enables the classification and aggregation of phenotypic and clinical data within a single environment and allows analysis of that data at unprecedented speed and scale. The combination of Illumina's BaseSpace cloud computing environment for next-generation sequencing with NextBio's platform for integrating patient data will allow us to deliver solutions that seamlessly integrate the entire workflow from sample to result."

NextBio's platform allows customers to quickly compare their experimental results against thousands of published and private data sets by means of a unique correlation engine, which pre-computes billions of significant connections between disparate data elements and helps discover new associations.

NextBio Clinical, which in 2012 passed an independent HIPAA audit, is designed for seamless integration with existing clinical and research systems.

Backed by highly scalable Software as a Service (SaaS) enterprise technology, it is capable of analyzing petabytes of data.

NextBio's database platforms are currently used by researchers and clinicians in more than 50 commercial and academic institutions. NextBio will be integrated into Illumina's newly formed Enterprise Informatics business under the leadership of Nick Naclerio, SVP of Corporate and Venture Development and General Manager of Enterprise Informatics.

NextBio co-founder Ilya Kupershmidt and Chief Technology Officer Satnam Alag will continue to provide scientific and technical leadership as part of the new business unit.

Illumina is confirming its 2013 financial guidance provided on October 21, 2013. The transaction is expected to close by the end of October.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Illumina Accelerator Welcomes First International Fellow
Illumina Accelerator has expanded their startup pool with the Center of Individualized Diagnostics (CID).
Wednesday, August 24, 2016
Illumina Applauds FDA’s Issuance of Draft Guidances
Company has supported the FDA in their efforts to provide a flexible and streamlined approach to the oversight of NGS diagnostic test.
Friday, July 08, 2016
Illumina Announces Agricultural Greater Good Initiative Grant
The grant program is designed to help identify measures that can increase crop yields and improve livestock welfare and productivity to alleviate poverty and hunger in the developing world.
Tuesday, June 14, 2016
ArcherDX, Illumina Launch Collaboration
Agreement to bring multiple Archer® assays through the FDA approval process.
Tuesday, May 31, 2016
Illumina Registers MiSeqDx System in South Korea
Regulatory milestone clears path for clinical laboratories to use Illumina NGS technology.
Tuesday, May 10, 2016
Illumina Files Patent Infringement Suit against Genoma SA
Company has announced that it has filed a patent infringement suit against Genoma SA in the Switzerland for Infringement of NIPT Patents.
Friday, April 22, 2016
Illumina Invests In New Venture Fund
Illumina will commit $100M over 10 years to drive genomic technology development.
Friday, April 15, 2016
Illumina Applies CE Mark to VeriSeq™ NIPT Analysis Software
Company has announced that it has applied the CE mark to expand the use of VeriSeq NIPT analysis software in clinical laboratories.
Thursday, February 25, 2016
Illumina Sues Oxford Nanopore for Patent Infringement
Illumina, Inc. has announced that the company filed lawsuits against Oxford Nanopore Technologies Ltd. and Oxford Nanopore Technologies, Inc. (ONT).
Wednesday, February 24, 2016
Genomics England, Illumina Enter Bioinformatics Partnership
Illumina, and Genomics England have announced a partnership to develop a platform and knowledge base that can be used to improve and automate genome interpretation.
Thursday, February 11, 2016
Illumina Signs Multiple Biobank Deals
Company has signed four deals to advance personalized medicine and improve health care.
Tuesday, February 09, 2016
Illumina Signs Multiple Biobank Deals
MEGA array family and next-generation sequencing to support comprehensive genomics approach toward personalized medicine.
Wednesday, February 03, 2016
Illumina Appoints Dr. Frances Arnold to its Board of Directors
Dr. Arnold is the Director of the Donna and Benjamin M. Rosen Bioengineering Center.
Sunday, January 31, 2016
Illumina Appoints Dr. Frances Arnold to Its Board of Directors
Illumina, Inc. has announced that Dr. Frances Arnold has joined the company’s Board of Directors. Dr. Arnold manages a research group at the California Institute of Technology and is the Director of the Donna and Benjamin M. Rosen Bioengineering Center.
Thursday, January 28, 2016
Illumina Acquires Conexio Genomics
Acquisition strengthens company’s ability to deliver sample-to-report solutions for HLA typing.
Wednesday, January 27, 2016
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Transporting Microscopic Cargo Between Human Cells
Scientists have developed a virus-inspired delivery system for material transport between cells.
Tissue Damage Is Key for Cell Reprogramming
Researchers have shown tissue damage is important for cells to return to an embryonic state for cell reprogramming.
Metabolite Promotes Cancer Cell Transformation
Researchers have identified a metabolite that promotes cancer cell transformation and colorectal cancer spread.
Improving Drug Production with Computer Model
A model has been developed that can be used to improve and accelerate the production of biotherapeutics, cancer drugs, and vaccines.
Bird Flu Confirmed in the Netherlands
An outbreak of H5 avian influenza was confirmed in the Flevoland province of the Netherlands.
Pasteurised Bacterium Reduces Obesity and Diabetes
Researchers have discovered that an intestinal bacterium provides a lasting effect on the intestinal barrier.
Turning Off Asthma Attacks
Researchers discover a critical cellular “off” switch for the inflammatory immune response that causes asthma attacks.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!